EQL Pharma Management
Management criteria checks 3/4
EQL Pharma's CEO is Axel Schorling, appointed in Aug 2022, has a tenure of 2.33 years. total yearly compensation is SEK2.26M, comprised of 72.6% salary and 27.4% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth €2.11M. The average tenure of the management team and the board of directors is 2.3 years and 4.9 years respectively.
Key information
Axel Schorling
Chief executive officer
SEK 2.3m
Total compensation
| CEO salary percentage | 72.6% |
| CEO tenure | 2.3yrs |
| CEO ownership | 1.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | SEK 31m |
| Jun 30 2024 | n/a | n/a | SEK 26m |
| Mar 31 2024 | SEK 2m | SEK 2m | SEK 23m |
Compensation vs Market: Axel's total compensation ($USD205.68K) is below average for companies of similar size in the German market ($USD900.29K).
Compensation vs Earnings: Insufficient data to compare Axel's compensation with company performance.
CEO
Axel Schorling (38 yo)
2.3yrs
Tenure
SEK 2,262,000
Compensation
Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 18.9yrs | SEK 250.00k | no data | |
| President & CEO | 2.3yrs | SEK 2.26m | 1.07% € 2.1m | |
| Chief Financial Officer | 3yrs | no data | 0.047% € 93.2k | |
| Chief Operating Officer | 2.3yrs | no data | 0.070% € 137.1k | |
| Chief Commercial Officer | no data | no data | 0.88% € 1.7m | |
| Chief Business Development Officer | 1.8yrs | no data | no data |
2.3yrs
Average Tenure
50yo
Average Age
Experienced Management: 7JK's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 18.9yrs | SEK 250.00k | no data | |
| Independent Director | 4.9yrs | SEK 100.00k | 0.0086% € 17.0k | |
| Independent Director | 6.3yrs | SEK 100.00k | 0.034% € 67.9k | |
| Independent Director | 3.9yrs | SEK 100.00k | 0.034% € 67.9k | |
| Independent Director | 3.9yrs | SEK 100.00k | no data |
4.9yrs
Average Tenure
57yo
Average Age
Experienced Board: 7JK's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 01:39 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EQL Pharma AB (publ) is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Commissioned Research |